c-rad.comCrawled Nov 18, 2026
C-RAD secures an **8 MSEK order** from a top Northeastern U.S. academic medical center for multiple **Catalyst⁺ HD systems**, expanding its radiation therapy market share. The vendor-agnostic technology integrates with various linear accelerator platforms, reinforcing C-RAD’s position as a leader in Surface Guided Radiation Therapy (SGRT).
C-RAD, a leader in surface-guided radiation therapy (SGRT), plans to repurchase up to **600,000 Class B shares** for **SEK 20 million** by its 2027 Annual General Meeting. The move aims to optimize the company’s capital structure by reducing share capital. The Board of Directors approved the program following authorization from the **2026 Annual General Meeting**.
C-RAD reports on its third-quarter financial performance, highlighting challenges faced during the period. The company emphasizes a strengthened portfolio as a key development amid operational difficulties.
C-Rad is set to present its interim report and third-quarter financial results for 2026. The company will host a presentation on Thursday, October 22, detailing performance metrics and operational updates for investors and stakeholders.
C-RAD demonstrates its **Catalyst⁺ family** of Surface Guided Radiation Therapy (SGRT) systems at **ASTRO 2026** in Boston, highlighting improved accessibility. The company also unveils **interoperability between its Sentinel product and United Imaging’s systems**, expanding compatibility. Attendees get an early preview of C-RAD’s upcoming **next-generation workflow platform**, designed to modernize radiation therapy software.
C-RAD reports revenue growth and improved profitability in its Q2 2026 interim results. The company highlights financial progress without specifying figures or key drivers in the brief statement.

C-Rad is a Swedish medical technology company making surface guided radiation therapy solutions, listed on Nasdaq Stockholm.